These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 9698691)

  • 61. Neoadjuvant therapy prior to radical prostatectomy: pro.
    Fair WR; Garnick MB
    Urology; 1996 Oct; 48(4):535-8. PubMed ID: 8886055
    [No Abstract]   [Full Text] [Related]  

  • 62. Consensus development summaries. The management of clinically localized prostate cancer. National Institutes of Health.
    Conn Med; 1987 Sep; 51(9):607-10. PubMed ID: 3311616
    [No Abstract]   [Full Text] [Related]  

  • 63. Editorial comment on: Additional surgical intervention after radical prostatectomy, radiation therapy, androgen-deprivation therapy, or watchful waiting.
    Aus G
    Eur Urol; 2007 Oct; 52(4):1043. PubMed ID: 17933028
    [No Abstract]   [Full Text] [Related]  

  • 64. [Treatment for cancer specifically diagnosed in high-aged population, prostate cancer].
    Miki T
    Nihon Ronen Igakkai Zasshi; 2006 Jan; 43(1):71-3. PubMed ID: 16521807
    [No Abstract]   [Full Text] [Related]  

  • 65. [Review of phase III clinical trials on combined anti-androgen therapies in patients with metastasized prostatic cancer].
    Denis L; Dalesio O; Murphy G
    Prog Urol; 1993 Feb; 3(1):75-85. PubMed ID: 8485599
    [No Abstract]   [Full Text] [Related]  

  • 66. Early Androgen Deprivation Therapy Improves Survival, But How Do We Determine in Whom?
    Frydenberg M; Woo HH
    Eur Urol; 2018 Apr; 73(4):519-520. PubMed ID: 29373214
    [No Abstract]   [Full Text] [Related]  

  • 67. [New substances in therapy of advanced prostate cancer].
    Kriegmair M; Schmeller NT
    Fortschr Med; 1991 Sep; 109(28):568-9. PubMed ID: 1721889
    [No Abstract]   [Full Text] [Related]  

  • 68. Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer.
    Carroll PR; Kantoff PW; Balk SP; Brown MA; D'amico AV; George DJ; Grossfeld GD; Johnson CS; Kelly WK; Klotz L; Lee WR; Lubeck DP; Mcleod DG; Oh WK; Pollack A; Sartor O; Smith MR; Hart C;
    Urology; 2002 Sep; 60(3 Suppl 1):1-6. PubMed ID: 12231036
    [No Abstract]   [Full Text] [Related]  

  • 69. Prostate cancer update.
    Rosenberg J; Small EJ
    Curr Opin Oncol; 2003 May; 15(3):217-21. PubMed ID: 12778015
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Treatment of prostate cancer].
    Kan DV; Dunaevskiĭ IaL
    Urol Nefrol (Mosk); 1981; (4):29-34. PubMed ID: 7268980
    [No Abstract]   [Full Text] [Related]  

  • 71. [Clinical significance and indication of androgen ablation therapy in radiation therapy for localized prostate cancer].
    Akimoto T
    Nihon Rinsho; 2011 Jun; 69 Suppl 5():418-23. PubMed ID: 22208014
    [No Abstract]   [Full Text] [Related]  

  • 72. Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): a new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy.
    Parker C; Sydes MR; Catton C; Kynaston H; Logue J; Murphy C; Morgan RC; Mellon K; Morash C; Parulekar W; Parmar MK; Payne H; Savage C; Stansfeld J; Clarke NW;
    BJU Int; 2007 Jun; 99(6):1376-9. PubMed ID: 17428247
    [No Abstract]   [Full Text] [Related]  

  • 73. Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer.
    Bagshaw MA
    Prostate; 1999 May; 39(3):151-2. PubMed ID: 10334102
    [No Abstract]   [Full Text] [Related]  

  • 74. Prostate cancer.
    Chisholm G; Rana A
    Practitioner; 1992 Jun; 236(1515):610-7. PubMed ID: 1454729
    [No Abstract]   [Full Text] [Related]  

  • 75. Stage D1 prostate cancer--delayed androgen deprivation.
    Richie JP
    Urology; 1997 Dec; 50(6):838-9. PubMed ID: 9426710
    [No Abstract]   [Full Text] [Related]  

  • 76. Androgen deprivation therapy in high-risk prostate cancer.
    Buyyounouski MK
    Oncology (Williston Park); 2010 Aug; 24(9):806, 809. PubMed ID: 20923033
    [No Abstract]   [Full Text] [Related]  

  • 77. Clinical assessment and management of stage T3 prostate cancer.
    Newling DW
    Eur Urol; 1997; 32 Suppl 3():55-9. PubMed ID: 9267786
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Evidence-based clinical practice Guidelines for Prostate Cancer (Summary - JUA 2006 Edition).
    Kamidono S; Ohshima S; Hirao Y; Suzuki K; Arai Y; Fujimoto H; Egawa S; Akaza H; Hara I; Hinotsu S; Kakehi Y; Hasegawa T;
    Int J Urol; 2008 Jan; 15(1):1-18. PubMed ID: 18184166
    [No Abstract]   [Full Text] [Related]  

  • 79. Management of Men with Prostate-specific Antigen Failure After Prostate Radiotherapy: The Case Against Early Androgen Deprivation.
    Brand D; Parker C
    Eur Urol; 2018 Apr; 73(4):521-523. PubMed ID: 29306513
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Treatment options for localized prostate carcinoma.
    Klein FA
    Va Med; 1985 Jul; 112(7):444-9. PubMed ID: 3898626
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.